|
Model Number OP-08W |
Device Problems
Biocompatibility (2886); Adverse Event Without Identified Device or Use Problem (2993)
|
Patient Problem
Hypersensitivity/Allergic reaction (1907)
|
Event Date 11/17/2023 |
Event Type
Injury
|
Manufacturer Narrative
|
The complaint prodcut has not been analyzed yet since it has just arrived in japan.However, we investigated manufacturing and quality control records based on the lot number.According to the investigation, no potential for malfunction was found and no similar event has been reported with this lot number globally so far.Since hypersensitivity occurred during treatment using the device, it was determined that a causal relationship "cannot be denied." the physician determined this event as "serious injury", and we also determined this event as "serious injury" since the patient was hospitalized.The cause of hypersensitivity might be an allergy to the membrane material of this product, but it cannot be determined.As for an allergic reaction, anaphylactoid reaction is described in ifu " e.Precautions 13.Monitor the patient constantly during treatment with the plasmaflo¿ op-05w(a).In the event of any of the following during treatment, immediately ensure the safety of the patient and take appropriate measures in accordance with the directions of the responsible physician.Presence of hemoglobin in separated plasma, due to hemolysis.The other potential reactions due to available substitute fluid such as fresh frozen plasma, plasma protein fraction are anaphylactoid reactions, hypocalcemia and infection." we are going to prepare a follow-up report as soon as we get the result of the analysis of the complaint product.We will continue to monitor the occurrence of similar events carefully.
|
|
Event Description
|
This incident occurred in france.Plasmaflo op is identical model to op-05w(a) marketed in us.This event occurred when double filtration plasmapheresis (dfpp) was performed on a patient using plasmaflo op.The patient was treated with dfpp for a recurrence of segmental and focal hyalinosis on a renal graft on (b)(6) 2023.20 minutes after starting the treatment, hypersensitivity such as tingling sensation in the lips, paresthesia on the tip of the tongue, nausea, vomiting, diarrhea, abdominal pain, and hypothermia appeared.Double filtration plasma exchange therapy was discontinued.Phloroglucinol, ondansetron, and paracetamol were administered as per ordered.Also, 500 ml of sodium chloride was administered via iv.The patient was hospitalized overnight and recovered.
|
|
Manufacturer Narrative
|
The inspection of the returned complaint product was completed at manufacturing site on december 27, 2023.According to the inspection, there were no abnormalities found and no similar event has been reported with this lot number globally so far.We will continue to monitor the occurrence of similar events carefully.
|
|
Search Alerts/Recalls
|
|
|